Some investors asked questions on the investor interactive platform: Hello, Secretary Dongslotsiteswithwelcomebonus, consult the following questionsslotsiteswithwelcomebonus:1slotsiteswithwelcomebonus. Your company obtained terbium sulfateslotsiteswithwelcomebonusAre talin solution for aerosol inhalation and other medicines on the market and what is their market share? 2. The country vigorously develops synthetic biotechnology. Does the company have synthetic biological products or technology reserves? thank
Huluwa (605199.SH) stated on the investor interactive platform on May 14 that the company obtained the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration on April 23, 2024 for terbutaline sulfate solution for nebulized inhalation. No sales have yet been formed. There are currently no synthetic biological products or technical reserves.
(Article source: Daily Economic News)